Adding Desloratadine to Rheumatoid Arthritis Treatment
Treatments studied
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This study tests whether desloratadine, an allergy medication, can help reduce rheumatoid arthritis symptoms when added to your current treatments. Researchers want to see if it reduces joint swelling and pain alongside your existing therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an active rheumatoid arthritis diagnosis confirmed by standard criteria
- Your disease activity score (a measure of joint inflammation) is above 2.6
- You are between 18 and 60 years old
- You are currently taking methotrexate as part of your arthritis treatment
- You do not have kidney or liver disease
- You are willing and able to sign a consent form
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether two drugs—roflumilast and desloratadine—added to your current rheumatoid arthritis medications can reduce joint inflammation and pain. You'd take these as add-ons to your existing treatment to see if they help control your disease better.
This study tests whether adding roflumilast, a new medication, to your current rheumatoid arthritis treatment can help reduce joint inflammation and improve your symptoms. You would take it alongside methotrexate, a common RA medication you may already be using.
This trial compares two additional medicines (diosmin or rebamipide) taken with standard arthritis treatment to see if they help reduce joint pain and swelling better than standard treatment alone.
This trial studies whether certain medicines can improve how active rheumatoid arthritis is. If you have rheumatoid arthritis and do not have significant liver or kidney problems, you may be able to join.
This Phase 1/2 study tests whether fexofenadine (an allergy medicine) can improve symptoms and inflammation in people with active rheumatoid arthritis. Participants may be assigned to different treatment groups, and the study looks at safety and early signs of benefit.
This study compares two combination treatments for rheumatoid arthritis in people whose current methotrexate or leflunomide isn’t working well enough. It aims to see whether adding a targeted therapy works better than the standard add-on of sulfasalazine plus hydroxychloroquine.
Hear when a new Rheumatoid arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.